Valuation: Gilead Sciences, Inc.

Market Cap 167B 146B 135B 124B 234B 16,050B 239B 1,608B 632B 7,859B 626B 612B 27,067B P/E 2026 *
-48.4x
P/E 2027 * 17x
Enterprise Value 176B 154B 142B 131B 247B 16,961B 252B 1,699B 667B 8,305B 662B 647B 28,603B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5.15x
Free-Float
99.88%
Yield 2026 *
2.42%
Yield 2027 * 2.5%
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+69.18%+57.76% - - 169B
+0.85%-3.11%+49.29%+162.34% 1,043B
+1.23%-2.34%+53.56%+58.28% 602B
+0.04%+1.83%+33.53%+87.11% 449B
+0.78%-0.39%+30.44%+23.23% 327B
+1.41%+0.56%+31.41%+47.13% 279B
-0.27%-5.69%+20.68%+21.99% 264B
-1.42%+0.73%+22.50%+61.06% 201B
-0.36%+3.30%+1.79%-31.03% 143B
-0.08%-2.19%+3.43%+37.68% 123B
Average +6.90%-1.04%+27.40%+51.98% 381.24B
Weighted average by Cap. +3.20%-1.97%+37.33%+82.33%

Financials

2026 *2027 *
Net sales 30.47B 26.64B 24.59B 22.65B 42.71B 2,933B 43.65B 294B 115B 1,436B 114B 112B 4,947B 32.4B 28.33B 26.14B 24.08B 45.42B 3,119B 46.42B 312B 123B 1,527B 122B 119B 5,260B
Net income -3.39B -2.96B -2.74B -2.52B -4.75B -326B -4.86B -32.71B -12.85B -160B -12.73B -12.45B -551B 9.76B 8.54B 7.88B 7.26B 13.68B 940B 13.99B 94.15B 36.98B 460B 36.66B 35.85B 1,585B
Net Debt 9.46B 8.27B 7.63B 7.03B 13.26B 911B 13.55B 91.24B 35.84B 446B 35.53B 34.74B 1,536B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.28USD
Average target price
158.30USD
Spread / Average Target
+17.89%

Quarterly revenue - Rate of surprise